U.S. License Holder:
Centocor Inc. (Janssen Biotech, Inc.)
Date of License:
December-22-1994
Last Update:
Dec-15-2024
FDA-Approved Indications
ReoPro (abciximab) is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications:
in patients undergoing percutaneous coronary intervention;
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.